Rua Bioscience launches NZ$2m rights offer amid strong revenue growth

Rua Bioscience announced a pro-rata renounceable rights issue on November 3, 2025, offering one new share for every three existing shares at NZ$0.025 per share, aiming to raise up to NZ$2 million. This capital raise, combined with proceeds from a Gisborne property sale, is intended to fund the company to a self-sustaining position and support working capital and marketing for new products in key markets including Germany, Australia, UK, and Czechia. The issue price reflects a 35% discount to the 5-day volume-weighted average price up to October 31, 2025.

The announcement follows strong revenue growth, with FY25 revenue reaching NZ$1.90 million, a significant increase from NZ$0.32 million in FY24. The company expects revenue to exceed NZ$3 million by the end of FY26, with Q1 FY26 sales already setting a new record at NZ$0.56 million. This rights offer follows recent shareholder approvals on October 28 and 29, 2025, for various resolutions, including the re-election of a director and authorization for directors to issue up to 49,993,744 new ordinary shares at not less than NZ$0.03 each.

The offer’s key dates include an Ex Rights Date of Friday, November 7, 2025, an opening date of Tuesday, November 11, 2025, and a closing date of Friday, November 28, 2025. Allotment and commencement of trading for new shares are scheduled for Thursday, December 4, 2025. Eligible shareholders can also apply for additional shares via an Oversubscription Facility.